Global Biosimilars Market & Biosimilars Clinical Pipeline Analysis in New Research Report Published by KuicK Research
Delhi, India (PRWEB) March 19, 2014 -- “Global Biosimilars Market & Pipeline Insight 2018” Report Highlights
• Global Biosimilars Market Overview
• Global Biosimilars Market Dynamics
• Regulatory Framework Across Key Markets
• Biosimilar Clinical Pipeline Insight by Indication, Country & Phase
• Marketed Biosimilars Profiles by Indication & Country
• Competitive Landscape
“Global Biosimilars Market & Pipeline Insight 2018” Report Findings:
• Number of Biosimilars in Clinical Phase: 305
• Marketed Biosimilars: 66
• Maximum Number of Biosimilars in Preclinical Phase: 73
• Global Biosimilars Market Growth (2013-2018): More than 25% CAGR
• Europe Dominates the Clinical Trial Development of Biosimilars
The global biosimilars market is categorized into monoclonal antibody biosimilars (mAbs), insulins, interferons, erythropoetins, filgrastim, somatropin and follicle stimulating hormone (FSH). Among the segments of the biosimilars market, the monoclonal antibodies (mAbs) and insulin market would witness maximum growth, with these two segments accounting for a dominant share of 46% of the total global biosimilars market by 2018. Additionally, with the mAbs having one of the strongest R&D pipeline in the biologics market, it is expected that many new next-generation technologies which would push mAb therapeutics into newer areas such as solid tumors, cardiovascular and neurological disorders would be introduced into the market.
“Global Orphan Drug Market Outlook 2018” Report Findings:
• Orphan Designated Drugs in Clinical Phase: 600
• Marketed Orphan Designated Drugs: 281
• Highest Number of Drugs in Phase-2 Trial: 231
• US Dominates Clinical Trial Process: 350 in Pipeline (Research till Registration)
• Indication for Clinical Trials for Orphan Drug: More than 30% for Cancer Treatment
• Share of Biological in Orphan Drug: More than 60%
• Key Market: US (Sales > US$ 40 Billion)
“Global Orphan Drug Market Outlook 2018” Report Highlights
• Why Shift to Orphan Drugs
• Global & Regional Orphan Drug Market Overview
• Orphan Drug Designation Criteria Across US, Europe & Asia
• Market Specific Reimbursement Policy for US, Europe & Asia
• Regulatory Framework for US, Europe & Asia
• Orphan Drug Pipeline by Phase, Orphan Designated Indication & Country
• Competitive Landscape
The orphan drugs enjoy significant competitive advantages in the market owing to the market exclusivity period after the drug has been authorized. Through this clause, the manufacturer of orphan drugs is given a monopoly status in the market because according to the law, no other company is allowed to market the orphan drugs during the exclusivity period. Additionally, this monopolistic power is further strengthened with the fact that no other alternative health technology exists for many orphan drugs.
The major drivers for companies to increasingly invest in orphan drugs include government incentives for drug development and strong support from the FDA and EU Commission in special protocols. Inspite of pharma companies facing many obstacles in this field, this segment of orphan drugs is likely to have the potential to provide the key to recovery and stability within the market.
For More information visit: http://www.kuickresearch.com
For Report Sample Contact:
Mr. Neeraj Chawla
neeraj(at)kuickresearch(dot)com
+91-11-47067990
Recent Reports Publication:
• Cancer Gene Therapy Market Analysis
• Global Peptide Therapeutics Market and Pipeline Insight
• Global Monoclonal Antibodies Pipeline Analysis
• Global RNA Interference (RNAi) Therapy Market Outlook 2018
• HIV Vaccine Market Opportunity & Clinical Pipeline Analysis
• Global Cell Therapy Market & Pipeline Insight
• Global Radiopharmaceuticals Market Insight
• US Orphan Drug Market Outlook 2018
• Europe Orphan Drug Market Outlook 2018
• US Cancer Vaccine Market Outlook 2018
• South Korea Biosimilar Market Analysis
Neeraj Chawla, kuickresearch, http://www.kuickresearch.com/, +91 11-47067990, [email protected]
Share this article